Skip to Content
Merck
CN

A9950

Aniracetam

≥98%

Synonym(s):

1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C12H13NO3
CAS Number:
72432-10-1
Molecular Weight:
219.24
NACRES:
NA.77
PubChem Substance ID:
24277955
UNSPSC Code:
12352200
MDL number:
MFCD00153767

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3

SMILES string

COc1ccc(cc1)C(=O)N2CCCC2=O

InChI key

ZXNRTKGTQJPIJK-UHFFFAOYSA-N

assay

≥98%

originator

Roche

Gene Information

human ... GRM1(2911), GRM2(2912), GRM3(2913), GRM4(2914), GRM5(2915), GRM6(2916), GRM7(2917), GRM8(2918)
rat ... Gria1(50592)

Looking for similar products? Visit Product Comparison Guide

Application

Aniracetam has been used in the inhibition screening assays for kinase enzyme.

Biochem/physiol Actions

Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.
Aniracetam is a piracetam analog and has low bioavailability due to rapid excretion. It enhances the cognitive thinking and is effective for treatment of sleep and behavioral disorders. Aniracetam is prescribed for anxiety and also enhances learning and memory in situations with induced damage of the brain.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BGBB6258V
BGBB6258
123H38161
056K3797
129H1582

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Julia Vaglenova et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33(5), 1071-1083 (2007-07-05)
Specific pharmacological treatments are currently not available to address problems resulting from fetal ethanol exposure, described as Fetal Alcohol Syndrome or Fetal Alcohol Spectrum Disorders (FASD). The present study evaluated the therapeutic effects of aniracetam against cognitive deficits in a
A Pittaluga et al.
Naunyn-Schmiedeberg's archives of pharmacology, 359(4), 272-279 (1999-05-27)
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic
Kazuo Nakamura
CNS drug reviews, 8(1), 70-89 (2002-06-19)
Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new
Chrysi C Koliaki et al.
CNS neuroscience & therapeutics, 18(4), 302-312 (2011-11-11)
Dementia constitutes an increasingly prevalent cognitive disorder with serious socioeconomic implications. In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a
Rudolf Mueller et al.
Bioorganic & medicinal chemistry letters, 21(13), 3923-3926 (2011-06-04)
AMPA receptors (AMPARs) are an increasingly important therapeutic target in the CNS. Aniracetam, the first identified potentiator of AMPARs, led to the rigid and more potent CX614. This lead molecule was optimized in order to increase affinity towards the AMPA
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service